Unknown

Dataset Information

0

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone.


ABSTRACT:

SUBMITTER: Korde N 

PROVIDER: S-EPMC8251553 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6593978 | biostudies-literature
| S-EPMC6055619 | biostudies-literature
| S-EPMC5436074 | biostudies-literature
| S-EPMC8605887 | biostudies-literature
| S-EPMC7898514 | biostudies-literature
| S-EPMC7714092 | biostudies-literature
| S-EPMC9240591 | biostudies-literature
| S-EPMC6662597 | biostudies-literature
| S-EPMC7196059 | biostudies-literature
| S-EPMC9305600 | biostudies-literature